Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PGG-L1NA
- Development stage
- Preclinical
- Lead developer
- PrimeGen Biotech
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies
01
Overview
PGG-L1NA is an investigational exosome-based therapy being developed by PrimeGen for the treatment of chronic liver disease. It is part of PrimeGen's exosome program, which likely utilizes exosomes derived from their proprietary "stemXcell" platform, featuring Triple Activated Mesenchymal Stem Cells (MSCs). The therapy is designed to leverage the paracrine and immunomodulatory effects of MSC-derived exosomes to address the underlying inflammation and fibrotic processes associated with chronic liver conditions. As of early 2026, the program is in the early stages of development, with specific molecular targets and clinical data not yet publicly disclosed.
Beyond the preview
Go deeper on PGG-L1NA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PGG-L1NA.